Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease
Author:
Open Access
- 30 April 2010
- journal article
- review article
- Published by Korean Society for Biochemistry and Molecular Biology - BMB Reports in BMB Reports
- Vol. 43 (4) , 233-244
Abstract
Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease GTPase;G2019S;Kinase;LRRK2;Parkinson's disease; Parkinson's disease (PD) is the second most common neurodegenerative disease, and 5-10% of the PD cases are genetically inherited as familial PD (FPD). LRRK2 (leucine-rich repeat kinase 2) was first reported in 2004 as a gene corresponding to PARK8, an autosomal gene whose dominant mutations cause familial PD. LRRK2 contains both active kinase and GTPase domains as well as protein-protein interaction motifs such as LRR (leucine-rich repeat) and WD40. Most pathogenic LRRK2 mutations are located in either the GTPase or kinase domain, implying important roles for the enzymatic activities in PD pathogenic mechanisms. In comparison to other PD causative genes such as parkin and PINK1, LRRK2 exhibits two important features. One is that LRRK2's mutations (especially the G2019S mutation) were observed in sporadic as well as familial PD patients. Another is that, among the various PD-causing genes, pathological characteristics observed in patients carrying LRRK2 mutations are the most similar to patients with sporadic PD. Because of these two observations, LRRK2 has been intensively investigated for its pathogenic mechanism (s) and as a target gene for PD therapeutics. In this review, the general biochemical and molecular features of LRRK2, the recent results of LRRK2 studies and LRRK2's therapeutic potential as a PD target gene will be discussed.Keywords
This publication has 113 references indexed in Scilit:
- Leucine-rich repeat kinase 2 induces α-synuclein expression via the extracellular signal-regulated kinase pathwayCellular Signalling, 2010
- Leucine-Rich Repeat Kinase 2 Regulates the Progression of Neuropathology Induced by Parkinson's-Disease-Related Mutant α-synucleinNeuron, 2009
- Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2Biochemical and Biophysical Research Communications, 2009
- Wild-type LRRK2 but not its mutant attenuates stress-induced cell death via ERK pathwayNeurobiology of Disease, 2008
- Expression of the LRRK2 gene in the midbrain dopaminergic neurons of the substantia nigraNeuroscience Letters, 2008
- Genome-wide Linkage Analysis of a Parkinsonian-Pyramidal Syndrome Pedigree by 500 K SNP ArraysThe American Journal of Human Genetics, 2008
- Mutations in the GIGYF2 (TNRC15) Gene at the PARK11 Locus in Familial Parkinson DiseaseThe American Journal of Human Genetics, 2008
- The Roc domain of leucine‐rich repeat kinase 2 is sufficient for interaction with microtubulesJournal of Neuroscience Research, 2008
- The Parkinson’s disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase thatstimulates kinase activityExperimental Cell Research, 2007
- Identification of potential protein interactors of Lrrk2Parkinsonism & Related Disorders, 2007